These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 19531676)

  • 1. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
    Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.
    Pardanani A; Lasho TL; Schwager S; Finke C; Hussein K; Pruthi RK; Tefferi A
    Leukemia; 2007 Aug; 21(8):1828-9. PubMed ID: 17460706
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].
    Fan Z; Zhang R; Shen YM; Fei HR; Zhu ZL; Cen JN
    Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):611-4. PubMed ID: 19175989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
    Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
    Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
    Deadmond MA; Smith-Gagen JA
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
    Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
    Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
    Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of the JAK2 gene mutation in familial myeloproliferative neoplasm and its clinical significance].
    Zhang YM; Hao LX; Wei Q; Wei YQ; Huang F; Zhang Y; Yin CX; Feng R
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):103-7. PubMed ID: 22730657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience.
    Laurenti L; Tarnani M; Nichele I; Ciolli S; Cortelezzi A; Forconi F; Rossi D; Mauro FR; D'Arena G; Del Poeta G; Montanaro M; Morabito F; Musolino C; Callea V; Falchi L; Tedeschi A; Ambrosetti A; Gaidano G; Leone G; Foà R
    Am J Hematol; 2011 Dec; 86(12):1007-12. PubMed ID: 21953617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of JAK2V617F mutation in patients with myeloproliferative disorders with TaqMan-MGB probe].
    Ruan GR; Chen SS; Li LD; Liu YR; Qin YZ; Li JL; Ma X; Wang FR; Jiang Q; Jiang B; Liu KY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2401-4. PubMed ID: 18036317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99.
    Johansson P; Kutti J; Andréasson B; Safai-Kutti S; Vilén L; Wedel H; Ridell B
    J Intern Med; 2004 Aug; 256(2):161-5. PubMed ID: 15257729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.
    Lussana F; Carobbio A; Salmoiraghi S; Guglielmelli P; Vannucchi AM; Bottazzi B; Leone R; Mantovani A; Barbui T; Rambaldi A
    J Hematol Oncol; 2017 Feb; 10(1):54. PubMed ID: 28228104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome.
    Masarova L; Newberry KJ; Pierce SA; Estrov Z; Cortes JE; Kantarjian HM; Verstovsek S
    Leuk Res; 2015 Aug; 39(8):822-7. PubMed ID: 26012362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
    Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
    Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
    Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
    PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.